Titre : | Pharmaceutical regulation failures and changes: Lessons learned from OxyContin abuse and diversion (2013) |
Auteurs : | O. H. GRIFFIN III ; J. F. SPILLANE |
Type de document : | Article : Périodique |
Dans : | Journal of Drug Issues (Vol.43, n°2, April 2013) |
Article en page(s) : | 164-175 |
Langues: | Anglais |
Discipline : | SAN (Santé publique / Public health) |
Mots-clés : |
Thésaurus mots-clés REGULATION ; OPIOIDES ; ABUS ; MEDICAMENTS ; MESUSAGE ; REGLEMENTATION ; SURVEILLANCE EPIDEMIOLOGIQUE ; INDUSTRIE DU MEDICAMENTThésaurus géographique ETATS-UNIS |
Résumé : | OxyContin, a controlled-release opioid developed and produced by Purdue Pharma, was given Food and Drug Administration (FDA) approval in December 1995. By 1999, to the apparent surprise of Purdue Pharma, the Drug Enforcement Administration (DEA), and the FDA, extensive reports of OxyContin abuse and diversion began to circulate. The drug abuse assessment liability system in the United States has often been criticized and the experience with OxyContin did nothing but buttress those criticisms. However, as seven investigational hearings conducted by the U.S. Congress would expose, several changes were made to the abuse liability assessment to correct deficiencies in the system which had aggravated OxyContin abuse and diversion - a welcome sign from what many have considered an American tragedy. |
Domaine : | Autres substances / Other substances |
Affiliation : | School of Criminal Justice, The University of Southern Mississippi, Hattiesburg, MS, USA |
Cote : | Abonnement |
Lien : | http://dx.doi.org/10.1177/0022042612467990 |
Accueil